U S Stem Cell Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of U S Stem Cell Inc (USRM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: U S Stem Cell Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 0M vs 0M combined for its competitors (20.7% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-2.6% annualized vs trailing 12 months), vs decelerating (-88.7%) for its tracked peer group.
- Profitability: Its -2,836.8% net margin compares with -7,566.3% for the peer group.
- Peer revenue share: U S Stem Cell Inc accounted for 69.2% of combined revenue among its tracked peer group, down from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
USRM Sales vs. its Competitors, Q4 2022
With a net margin of -2,836.77 %, U S Stem Cell Inc achieved higher profitability than its competitors (-7,566.29 %).
U S Stem Cell Inc generated 69.18 % of the combined sales of its peer group, down from 100.00 % a year earlier.
API endpoints for this dataset
U S Stem Cell Inc vs. its Competitors, Q4 2022
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in U S Stem Cell Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across U S Stem Cell Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| U s Stem Cell Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across U S Stem Cell Inc's competitor groups requires a Commercial License.
For context: the Medical Laboratories industry grew revenue 9.0% year over year, combined, vs -15.3% for U S Stem Cell Inc. U S Stem Cell Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
U S Stem Cell Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| U s Stem Cell Inc | - | No | No | Yes |
| Competitors combined (1) | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
USRM Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Mangoceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for U S Stem Cell Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of U s Stem Cell Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 U s Stem Cell Inc |
0.08 | 0.08 |
 Mangoceuticals Inc |
3.17 | 0.32 |
| SUBTOTAL | 3.25 | 0.40 |
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on U s Stem Cell Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
U S Stem Cell Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| U s Stem Cell Inc | 0 | - | - |
| Mangoceuticals Inc | 3 | 14,329 | -686,555 |
| PEERS TOTAL | 3 | 14,329 | -686,555 |
U S Stem Cell Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 41 companies in U S Stem Cell Inc's industry classification, broader than the peer set above. Market cap in millions of $.U S Stem Cell Inc ranks #0 of 41 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 809, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Natera Inc | 46,271 | 13.03 % |
| 2 | Iqvia Holdings Inc | 45,357 | 12.78 % |
| 3 | Ge Healthcare Technologies Inc | 37,155 | 10.47 % |
| 4 | Labcorp Holdings Inc | 30,530 | 8.60 % |
| 5 | Quest Diagnostics Inc | 1,234 | 5.2% |
| 6 | Koninklijke Philips Nv | 1,234 | 5.2% |
| 7 | Incyte Corporation | 1,234 | 5.2% |
| 8 | Guardant Health Inc | 1,234 | 5.2% |
| 9 | Medpace Holdings Inc | 1,234 | 5.2% |
| 10 | Charles River Laboratories International inc | 1,234 | 5.2% |
| 0 | U s Stem Cell Inc | 0 | 0.00 % |
Market cap and industry share for the rest of U S Stem Cell Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-29.
U S Stem Cell Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Laboratories industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (77 companies). See the full Medical Laboratories industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 71.03 % | 33.07 % (avg) | +38.0 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -5.80 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 0.00 % | 7.44 % (avg) | -7.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
U S Stem Cell Inc's Valuation vs Competitive Position
Valuation multiples vs the Medical Laboratories industry average (77 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Medical Laboratories industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 39.0x | - |
| EV / EBITDA | - | 21.1x | - |
| P/B | -0.3x | 4.4x | -4.7x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | - | -7.68 % (avg) | - |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
U S Stem Cell Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 6.58 % | 40.71 % | 79.05 % | 21.38 % | -54.15 % | -90.98 % | -27.55 % | -59.13 % |
| Operating Margin | -118.92 % | -37.61 % | -14.58 % | -16.38 % | -111.22 % | - | - | - |
| Return on Invested Capital | - | - | - | - | - | - | - | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
U S Stem Cell Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 809 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.00 % vs industry average 7.44 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on U S Stem Cell Inc's dedicated Suppliers and Customers pages, not here.
U S Stem Cell Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Latest-quarter revenue run-rate is decelerating (-2.6% annualized vs trailing 12 months).
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-88.7% annualized).
Methodology: see Methodology: SWOT Analysis.
U S Stem Cell Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| U s Stem Cell Inc | 0.00 | 0.01 | - |
| Mangoceuticals Inc | 0.62 | 0.68 | 0.00 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
U S Stem Cell Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| U s Stem Cell Inc | Q4 2022 | -15.3 % | - |
| Mangoceuticals Inc | Q2 2026 | -59.1 % | - |
| PEERS TOTAL | -53.7 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
U S Stem Cell Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| U s Stem Cell Inc | Q4 2022 | -43.0 % | - |
| Mangoceuticals Inc | Q2 2026 | -44.5 % | - |
U S Stem Cell Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| U s Stem Cell Inc | - | - | - |
| Mangoceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
U S Stem Cell Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| U s Stem Cell Inc | - | 0.96 |
| Mangoceuticals Inc | - | 10.05 |
| PEERS AVERAGE | - | 8.17 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.